

NORYVEXA BIOLABS

Corporate Press Kit — October 2026

Document ID: NX-PR-2026-006

Author: Noryvexa Communications

Publication date: 22 October 2026

Classification: Public — Educational Simulation

Version: 1.0

Company Profile

Noryvexa BioLabs is a fictional biotechnology organization operating within a controlled cybersecurity training scenario.

The organization represents a Paris-based research company specializing in computational biology, molecular diagnostics and scientific data infrastructure.

Scenario establishment: 2024

Primary location: Paris, France

Industry: Biotechnology and Life Sciences

Research focus: Computational Biology, Diagnostics and Research Data

Executive Leadership

Maya Delcourt — Chief Executive Officer

Dr. Elena Varek — Chief Scientific Officer

Lucas Neirin — Head of Bioinformatics

Sofia Marel — Clinical Research Lead

Adam Verne — IT Systems Administrator

Adrien Valmont — Information Security Lead

Research Portfolio

Atlas Bioinformatics — NX-RD-041

Computational workflows for molecular data analysis and scientific reproducibility.

Helix Diagnostics — NX-RD-052

Research into computational methods supporting molecular diagnostic analysis.

CellTrace Data — NX-RD-063

Scientific data management, reproducibility and collaboration workflows.

Selected Announcements

22 May 2026: Introduction of the Helix research program.

8 July 2026: Announcement of a fictional research collaboration framework.

16 September 2026: Publication of the CellTrace research roadmap.

14 October 2026: Atlas research initiative enters its next phase.

Media and Research Inquiries

Press: press@noryvexa.example

Research: research@noryvexa.example

General inquiries: contact@noryvexa.example

Usage Notice

All organization names, research programs, people and announcements in this document are fictional. The document is provided exclusively for educational OSINT and cybersecurity exercises.